Amicus Therapeutics Total Assets 2010-2022 | FOLD

Amicus Therapeutics total assets from 2010 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Amicus Therapeutics Annual Total Assets
(Millions of US $)
2021 $905
2020 $887
2019 $850
2018 $790
2017 $627
2016 $1,037
2015 $908
2014 $210
2013 $128
2012 $110
2011 $70
2010 $113
2009 $85
Amicus Therapeutics Quarterly Total Assets
(Millions of US $)
2022-03-31 $827
2021-12-31 $905
2021-09-30 $957
2021-06-30 $787
2021-03-31 $810
2020-12-31 $887
2020-09-30 $901
2020-06-30 $701
2020-03-31 $738
2019-12-31 $850
2019-09-30 $882
2019-06-30 $918
2019-03-31 $765
2018-12-31 $790
2018-09-30 $839
2018-06-30 $826
2018-03-31 $870
2017-12-31 $627
2017-09-30 $681
2017-06-30 $939
2017-03-31 $993
2016-12-31 $1,037
2016-09-30 $918
2016-06-30 $914
2016-03-31 $863
2015-12-31 $908
2015-09-30 $987
2015-06-30 $404
2015-03-31 $193
2014-12-31 $210
2014-09-30 $125
2014-06-30 $118
2014-03-31 $112
2013-12-31 $128
2013-09-30 $69
2013-06-30 $82
2013-03-31 $93
2012-12-31 $110
2012-09-30 $118
2012-06-30 $112
2012-03-31 $121
2011-12-31 $70
2011-09-30 $79
2011-06-30 $90
2011-03-31 $103
2010-12-31 $113
2010-09-30 $64
2010-06-30 $75
2010-03-31 $88
2009-12-31 $85
2009-09-30 $99
2009-06-30 $109
2009-03-31 $116
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.079B $0.306B
Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.?The company has one marketed medicine in its portfolio named Galafold which is the first and the only approved oral precision medicine for patients living with Fabry disease, having amenable genetic variants. Migalastat is a potent orally available inhibitor of alpha-Gal A.?The drug was granted an accelerated approval by the FDA for treating adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant. Galafold is the first and only oral therapy approved in the EU for the long-term treatment of adolescents with Fabry disease.?The lead pipeline candidate in the company's portfolio is AT-GAA, a differentiated biologic for Pompe disease. The company has one gene-therapy program in its pipeline CLN3, a type of Batten disease, being evaluated in a phase I/II study.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.724B 9.84
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.093B 15.93
Biohaven Pharmaceutical Holding (BHVN) United States $9.948B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.434B 0.00
Emergent Biosolutions (EBS) United States $1.592B 6.82
Arcus Biosciences (RCUS) United States $1.327B 33.64
Myovant Sciences (MYOV) United Kingdom $0.961B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.483B 0.00
Gelesis Holdings (GLS) United States $0.357B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.117B 24.00
SQZ Biotechnologies (SQZ) United States $0.092B 0.00